Pharma Stocks
Dr Reddy's sees sharpest intra-day rally since Sept 2020; stock surges 8%
The stock gained 9 per cent in two days after the pharma company reported better-than-expected revenue growth in March quarter (Q4FY22).
 "Dr Reddy's sees sharpest intra-day rally since Sept 2020; stock surges 8%")
Divis Labs sheds 14% in two days, hits 52-week low post Q4 results
The company has earmarked an aggressive capex of around Rs 2,000 crore over next two years in order to take a chunk of around $20 billion opportunity of APIs going off-patent over FY23-25.
 "Divis Labs sheds 14% in two days, hits 52-week low post Q4 results")
Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results
In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 per cent in Q4FY21
 "Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results")
Aurobindo hits 2-year low; dips 11% in a week on USFDA's 6 observations
Analysts at ICICI Securities expect Aurobindo Pharma's adjusted PAT to de-grow 30.4 per cent year-on-year (YoY) to Rs 557.90 crore in the March 2022 quarter.
 "Aurobindo hits 2-year low; dips 11% in a week on USFDA's 6 observations")
Sun Pharma slips over 2% after USFDA issues observations for Halol facility
In the past five days, the stock has fallen over 5 per cent. In comparison, the S&P BSE Sensex declined 3.75 per cent during the same period
 "Sun Pharma slips over 2% after USFDA issues observations for Halol facility")
Stocks to Watch: ICICI Bank, RIL, Tejas Network, Tata Metaliks, Religare
Stocks to Watch Today: Shares of pharma company - Aurobindo, Sun Pharma and Jubilant are likely to be in focus as the trio have recalled different products in the US market as per the latest USFDA
 "Stocks to Watch: ICICI Bank, RIL, Tejas Network, Tata Metaliks, Religare")
Nifty Pharma may have bottomed out; Aurobindo, Glenmark can rally up to 10%
The Nifty Pharma index has crossed its near-term resistance at 13,700, and may spurt another 1.5 per cent.
 "Nifty Pharma may have bottomed out; Aurobindo, Glenmark can rally up to 10%")
Pharma stocks surge on positive cues from Nifty healthcare, Cipla up 6%
Outlook for Indian drug exporters turned positive on prospects of firm exports amid the ongoing geo-political scenario, said analysts
 "Pharma stocks surge on positive cues from Nifty healthcare, Cipla up 6%")
Torrent Pharma's domestic show remains strong, brokerages turn positive
Progress on US sales will be key for further Torrent Pharma's stock gains
 "Torrent Pharma's domestic show remains strong, brokerages turn positive")
Natco Pharma gains 9% as firm launches generic version of Revlimid in US
In the past three months, Natco Pharma has outperformed the market by gaining 8 per cent, as compared to 8 per cent decline in the S&P BSE Sensex.
 "Natco Pharma gains 9% as firm launches generic version of Revlimid in US")
Stocks to Watch: Voda Idea, Wockhardt, KEC Intl, Tata Motors, Pharma, PSBs
Pharma shares are likely to be in limelight as NPPA may allow up to 10 per cent hike on scheduled drugs in the month of April.
 "Stocks to Watch: Voda Idea, Wockhardt, KEC Intl, Tata Motors, Pharma, PSBs")
Jagsonpal Pharma rallies 19% on open offer by Infinity Holdings Group
Infinity Holdings Group made an open offer to buy 26 per cent stake in the company at a price of Rs 235 per share
 "Jagsonpal Pharma rallies 19% on open offer by Infinity Holdings Group")
Lab stocks scramble for new growth in India as Covid gains halve
Surging healthcare spending and demand for Covid tests led to multifold share-price gains for pathology firms globally during the pandemic
 "Lab stocks scramble for new growth in India as Covid gains halve")
Two Cipla promoters sell 20 mn shares; promoter group now holds 34.23%
Chairman Y K Hamied and Vice Chairman MK Hamied, who are non-executive directors and promoters, have sold 2,01,69,756 shares on Tuesday
 "Two Cipla promoters sell 20 mn shares; promoter group now holds 34.23%")
Biocon gains 3%, at 6-month high in a weak market; stock up 18% in 3 weeks
Biocon said its subsidiary Biocon Pharma has received approval of its ANDA for Posaconazole Delayed-Release tablets from the US FDA.
 "Biocon gains 3%, at 6-month high in a weak market; stock up 18% in 3 weeks")
Torrent Pharma tumbles 14% on disappointing Q3 results
In Q3FY22, earnings before interest tax and depreciation and amortization (EBITDA) margins declined 490 bps YoY to 25.5 per cent driven by price erosion in the US.
 "Torrent Pharma tumbles 14% on disappointing Q3 results")
Aurobindo Pharma down 5% on USFDA warning letter for Hyderabad unit
The company believes that this will not impact the existing business from this facility.
 "Aurobindo Pharma down 5% on USFDA warning letter for Hyderabad unit")
Sun Pharma gains 4% on earnings optimism, stock scales a 5-year high
The better traction in the specialty segment and improvement in domestic business to drive the margin expansion in Q3.
 "Sun Pharma gains 4% on earnings optimism, stock scales a 5-year high")
Stocks to Watch: RIL, Wockhardt, IDBI Bk, SJVN, Titan, DMart, FMCG, Pharma
Pharma shares may be in focus as India's apex health research organization ICMR has raised concerns around the safety for use of the oral antiviral drug Molnupiravir
Stocks to Watch: RIL, Airtel, HUL, SBI, DB Realty, pharma, steel, textiles
Reliance Jio plans its biggest ever rupee bond sale, while Bharti Airtel shelves its plans to de-merge its core telecom business
 "Stocks to Watch: RIL, Airtel, HUL, SBI, DB Realty, pharma, steel, textiles")
